Ting H, Sun X G, Chuang M L, Lewis D A, Hansen J E, Wasserman K
Division of Respiratory and Critical Care Physiology and Medicine, Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA.
Chest. 2001 Mar;119(3):824-32. doi: 10.1378/chest.119.3.824.
The ventilatory equivalent for CO(2) (ie, the ratio of minute ventilation [VE] to carbon dioxide output [VCO(2)]) is increased in patients with primary pulmonary hypertension (PPH) consequent to an increase in physiologic dead space and alveolar ventilation. We wished to see whether the VE/V(2) ratio correlated with the abnormality in pulmonary hemodynamics in PPH patients and whether it changed in response to prostacyclin infusion.
Following right-sided heart catheterization, 10 patients with severe PPH were studied in the coronary-care unit while hemodynamic and gas exchange measurements were measured simultaneously before and after infusion with epoprostenol (Epo), a prostacyclin analog. Studies were performed at baseline and during IV infusion of two to three increasing dosages of Epo in 10 PPH patients (NYHA class III-IV). Four patients had radial artery catheters for simultaneous blood gas measurements. Nine healthy subjects who were matched by sex, height, and weight underwent gas exchange analyses only.
The mean (+/- SD) VE/VCO(2) ratio was higher in PPH patients than in control subjects (50.7 +/- 9.7 vs 30.6 +/- 3.8; p < 0.001). Thirteen measurements made in four patients showed that the VE/VCO(2) ratio correlated with the physiologic dead space/tidal volume ratio (r = 0.78; p = 0.002). The VE/VCO(2) ratio measurement at baseline correlated significantly with total pulmonary vascular resistance (TPVR) (r = 0.70; p = 0.02) but not with mean pulmonary artery pressure (mPAP) or cardiac index. During Epo infusion, the VE/VCO(2) ratio decreased with increasing dosage in 6 of 10 patients, with no change or slight increases in the 4 remaining patients. Considering all doses, the VE/VCO(2) ratio decreased significantly in response to the short-term administration of Epo. The decrease tended to parallel the pattern of decrease in TPVR, but the changes in both variables were too small to provide a statistically significant correlation. The mPAP did not change significantly in response to Epo infusion, although TPVR did change at the highest dosage.
In patients with severe PPH, the VE/VCO(2) ratio correlated significantly with TPVR but not with mPAP or cardiac index. The VE/VCO(2) ratio decreased systematically from baseline with the dose of Epo in some but not all patients. The VE/VCO(2) ratio and TPVR decreased significantly in response to Epo when all doses were considered. Further studies are needed to elucidate whether noninvasive gas exchange measurements may be clinically useful in the evaluation of the severity of pulmonary vascular disease and the effectiveness of pulmonary vasodilator therapy.
原发性肺动脉高压(PPH)患者因生理死腔和肺泡通气增加,其二氧化碳通气当量(即分钟通气量[VE]与二氧化碳排出量[VCO₂]的比值)升高。我们想了解VE/VCO₂比值是否与PPH患者的肺血流动力学异常相关,以及它是否会因输注前列环素而发生变化。
在进行右侧心导管检查后,对10例重度PPH患者在冠心病监护病房进行研究,在输注依前列醇(Epo,一种前列环素类似物)前后同时测量血流动力学和气体交换指标。对10例PPH患者(纽约心脏协会心功能分级III-IV级)在基线状态及静脉输注两到三种递增剂量的Epo期间进行研究。4例患者有桡动脉导管用于同步血气测量。9例年龄、身高和体重匹配的健康受试者仅进行气体交换分析。
PPH患者的平均(±标准差)VE/VCO₂比值高于对照组(50.7±9.7对30.6±3.8;p<0.001)。对4例患者进行的13次测量显示,VE/VCO₂比值与生理死腔/潮气量比值相关(r=0.78;p=0.002)。基线时的VE/VCO₂比值测量值与总肺血管阻力(TPVR)显著相关(r=0.70;p=0.02),但与平均肺动脉压(mPAP)或心脏指数无关。在输注Epo期间,10例患者中有6例的VE/VCO₂比值随剂量增加而降低,其余4例无变化或略有升高。综合所有剂量来看,短期输注Epo后VE/VCO₂比值显著降低。这种降低趋势与TPVR的降低模式平行,但两个变量的变化都太小,无法提供统计学上的显著相关性。尽管在最高剂量时TPVR确实发生了变化,但mPAP对输注Epo无显著变化。
在重度PPH患者中,VE/VCO₂比值与TPVR显著相关,但与mPAP或心脏指数无关。在部分但并非所有患者中,VE/VCO₂比值随Epo剂量从基线开始系统性降低。综合所有剂量来看,VE/VCO₂比值和TPVR对Epo有显著降低反应。需要进一步研究以阐明无创气体交换测量在评估肺血管疾病严重程度和肺血管扩张剂治疗效果方面是否具有临床实用性。